Comparison of surgical outcomes among open, laparoscopic, and robotic pancreatoduodenectomy: a single-center retrospective study

Wei Guo1†, Xiaofei Ye1†, Jiangfa Li1, Shiliu Lu1, Ming Wang1, Zefeng Wang1, Jianni Yao1, Shuiping Yu1,2,3*, Guandou Yuan1,2,3* and Songqing He1,2,3*

Abstract

Background: There is no general consensus on the feasibility and safety of robotic pancreatoduodenectomy (RPD) and whether it increases surgical risks. The purpose of this study was to assess the safety, feasibility, and rationality of RPD by comparing perioperative data among open pancreatoduodenectomy (OPD), laparoscopic pancreatoduodenectomy (LPD), and RPD performed in our center in recent years.

Methods: Clinical data of patients had undergone RPD (n = 32), LPD (n = 21), and OPD (n = 86) in The First Affiliated Hospital of Guangxi Medical University between January 2016 and June 2020 were retrospectively collected and analyzed.

Results: RPD required more time for operation (537.2 min vs. 441.5 min, p < 0.001) than OPD did, but less time to remove abdominal drainage tube (12.5 d vs. 17.3 d, p = 0.001). The differences between the RPD group and LPD group were interesting, as the two groups had similar operation time (537.2 min vs. 592.9 min, p = 1.000) and blood loss (482.8 ml vs. 559.5 ml, p > 0.05), but the RPD group had a higher activity of daily living score on postoperative day 3 (35.8 vs. 25.7, p = 0.0017) and a lower rate of conversion to OPD (6.5% vs. 38.1%, p = 0.011). Regarding complications, such as the postoperative pancreatic fistula, abdominal hemorrhage, intra-abdominal infection, bile leakage, reoperation, and perioperative mortality, there were no significant differences among the three groups.

Conclusions: Not only is RPD feasible and reliable, it also offers significant advantages in that it improves postoperative recovery of skills needed for everyday life, has a low conversion rate to open surgery, and does not increase surgical risks.

Keywords: Robotic surgery, Minimal invasive surgery, Pancreatoduodenectomy, Complications

Introduction

Pancreatoduodenectomy (PD) was first officially reported by Whipple in 1935 [1]. Since then, PD has been progressively acknowledged as a standard procedure for removing benign and malignant tumors from the head of pancreas and the periampullary region. The convoluted procedure involves broad resection and reconstruction of the digestive tract; therefore, it has invariably
been identified as one of the most complicated and risky operations.

Laparoscopic pancreatoduodenectomy (LPD) has been developed for approximately 27 years since this technology was reported by Gagner and Pomp for the first time in 1994 [2]. It is still controversial in the academic community because of its initially unacceptable feasibility and security. In recent years, LPD has been shown to provide obvious advantages such as less trauma, less delayed gastric emptying, less transfusion, faster postoperative recovery, and shorter hospital stay compared with conventional open pancreatoduodenectomy (OPD), benefiting from the breakthroughs of laparoscopic instruments and technologies [3–7]. Nevertheless, because it is complex and time-consuming, LPD is likely to tire surgeons, making it an unappealing treatment option.

Giulianotti et al. reported robotic pancreatoduodenectomy (RPD) for the first time in 2003, and it has since played a revolutionary part in the advancement of minimally invasive PD [8]. RPD can dramatically overcome some limitations of LPD by providing excellent ergonomics, instrument joints with 540° of movement, automatic tremor removal, and generation of high-definition of 3D images at 10–15× magnifications, all of which aid in the delicate and complex procedure and reduce the surgeon's fatigue [9, 10]. However, RPD has not been adopted universally as a result of the high expense of the instrument, technical challenges, risks of surgery, and oncological outcomes [9–12].

This study focuses on exploring the safety, feasibility, and justification of RPD by comparing the perioperative outcomes among OPD, LPD, and RPD groups based on PD data from the same pancreatic treatment team at the First Affiliated Hospital of Guangxi Medical University over the same time period.

Methods

Patients and data setting

From January 2016 to June 2020, the medical records of 183 patients who underwent PD procedures by three skilled surgeons with many years of training and who perform more than 20 PDs each year were retrospectively analyzed. To characterize patients consistently, we included the patients who underwent PD for benign, premalignant, or malignant indications. Exclusion criteria were as follows: (1) vascular involvement, (2) receipt of neoadjuvant chemotherapy or neoadjuvant radiotherapy before operation, (3) concomitant resection of another organ, and (4) patients unwilling to participate in this study or lost to follow-up (Fig. 1).

On admission, demographic and anthropometric data and a detailed clinical history were recorded, followed by laboratory and radiological investigations. The major laboratory data and their normal ranges were total bilirubin

![Fig. 1 Study flow diagram](image)
following circumstances: (1) the intraperitoneal adhesions were extensive and dense, and it was difficult to separate under laparoscopy, resulting in more bleeding; (2) the tumor was large and the operative field exposure was poor; (3) intraoperative blood loss reached 1000 ml, which is the warning line for conversion to OPD; (4) blood loss exceeded 1500 ml and the operation was unable to be completed; or (5) uncontrollable sudden and massive bleeding occurred.

Selection criteria for LPD and RPD were (1) patients in generally good condition, (2) capable of tolerating pneumoperitoneum for a long time, (3) without serious obesity (defined by a body mass index (BMI) ≥ 40), and (4) without vascular involvement or proximity to main vessels. LPD or RPD were converted to OPD under the following circumstances: (1) the intraperitoneal adhesions were extensive and dense, and it was difficult to separate under laparoscopy, resulting in more bleeding; (2) the tumor was large and the operative field exposure was poor; (3) intraoperative blood loss reached 1000 ml, which is the warning line for conversion to OPD; (4) blood loss exceeded 1500 ml and the operation was unable to be completed; or (5) uncontrollable sudden and massive bleeding occurred.

Definitions of surgical risks
Surgical risks were as follows: perioperative mortality; that is, death within 90 days after surgery or during hospitalization; postoperative pancreatic fistula (POPF) grades B and C, based on the new definition and grading system of the International Study Group for Pancreatic Fistula (ISGPF) [17]; post-pancreatectomy hemorrhage (PPH) [18], as defined by the International Study Group of Pancreatic Surgery (ISGPS); bile leakage, as defined by the International Study Group of Liver Surgery (ISGLS) [19]; intra-abdominal infection (IAI), as defined by the Surgical Infection Society (SIS) [20]; activity of daily living (ADL), measured according to the Barthe index scale; and pain, scored using was in the Wong-Baker FACES Pain Rating Scale (https://wongbakerfaces.org/).

Medical complications were defined according to the Clavien-Dindo classification [21], such as pneumonia (grade II), noninfectious diarrhea (grade I), anastomotic leakage (grade IIIb), biloma (grade IIIa) and wound infection (grade I, grade II, grade IIIa), etc. The treatments for these complications include antibiotics, percutaneous drainage or relaparotomy, early irrigation, and debridement.

Management of complications
Management of POPF: For grade B POPF, the management plan in our center is as follows. I. Drainage. The treatment of pancreatic fistula is based on unobstructed drainage. When drainage is not smooth, interventional ultrasound or CT-guided puncture drainage should be adopted. II. Infection control. Use broad spectrum antibiotics according to experience, keep the drainage fluid for culture, and adjust the use of antibiotics according to the results of drug sensitivity test. III. Nutritional support. Improving nutritional status is conducive to the healing of pancreatic fistula, and attention should be paid to the control of blood glucose, correction of hypoproteinemia and anemia, and maintenance of water and electrolyte balance. For Grade C POPF, surgical treatment should be considered when nonsurgical treatment is ineffective.

Management of PPH: Mild bleeding can be considered as a non-surgical treatment (such as application of hemostatic drugs), and the patient’s clinical manifestations should be closely observed. For moderate to severe abdominal bleeding, surgical treatment is recommended. If gastrointestinal bleeding is suspected, vascular intervention, endoscopy and other treatments can be selected according to technical conditions, and surgical hemostasis should be actively performed if necessary.

Management of bile leakage: Drainage, infection control, and nutritional support should be administered.

Management of IAI: Ultrasound or CT-guided percutaneous catheterization is recommended as the first choice within 24 h after diagnosis of intraperitoneal infection and initial empiric therapy should be administered with a broad-spectrum antibiotic. For severe gastrointestinal fistula or anastomotic fistula complicated with diffuse intraperitoneal infection, abscess puncture and drainage usually are not good or conservative treatments are often ineffective, laparotomy and external drainage or jejunostomy should be adopted according to the patient’s situation.

Statistical analysis
Statistical analyses were conducted using IBM SPSS Statistics v25. Continuous data were presented as the mean ± standard deviation or the range. Continuous parametric data of three group comparisons were analyzed through one-way ANOVA with Bonferroni correction for multiple comparison. Kruskal- Wallis was adopted to compare continuous nonparametric data. Chi-squared tests or Fisher’s exact test were performed for categorical data. A two-tailed significance level of p<0.05 was chosen.
Results

Patients and baseline characteristics

After screening based on our inclusion criteria, a total of 139 patients were enrolled in this study. The demographics of the three groups are included in Table 1. There were no statistical differences in preoperative clinical parameters, including age, sex, BMI, tumor size, TBil, ALB, Hb, malignant tumor and benign tumor, among the OPD, LPD, and RPD groups.

Perioperative outcomes

Perioperative outcomes are summarized in Table 2, postoperative complications in Table 3. Notably, no statistical differences were found regarding blood loss, blood transfusion, length of hospital stay, lymph node yield, or postoperative complications, such as PPH, bile leakage, IAI, POPF, reoperation and perioperative mortality. Although RPD required more operation time than OPD (537.2 min vs. 441.5 min, p < 0.001), the time to remove the abdominal drainage tube was considerably earlier for RPD (12.5 d vs. 17.3 d, p = 0.001). Compared with LPD, RPD had similar operative duration (537.2 min vs. 592.9 min, p = 1.000) and blood loss volume (482.8 ml vs. 559.5 ml, p > 0.05), but higher ADL on postoperative day 3 (35.8 vs. 25.7, p = 0.0017) and a lower rate of conversion to OPD (6.5% vs. 38.1%, p = 0.011). The higher ADL

Table 1 Baseline characteristics of the patients included

|               | OPD (n = 86) | LPD (n = 21) | RPD (n = 32) | P     | p1   | p2   | p3   |
|---------------|--------------|--------------|--------------|-------|------|------|------|
| Male          | 49           | 12           | 21           | 0.690 |      |      |      |
| Female        | 37           | 9            | 11           |       |      |      |      |
| Age           | 57.7 ± 12.3  | 52.1 ± 13.5  | 53.7 ± 14.4  | 0.119 |      |      |      |
| BMI           | 21.5 ± 3.0   | 22.6 ± 2.3   | 21.7 ± 3.0   | 0.314 |      |      |      |
| Tumor size    | 3.4 ± 2.1    | 3.7 ± 2.7    | 3.4 ± 1.9    | 0.916 |      |      |      |
| TBil          | 94.2 ± 115.0 | 86.2 ± 97.9  | 64.8 ± 70.0  | 0.395 |      |      |      |
| ALB           | 37.3 ± 3.9   | 37.5 ± 3.8   | 37.4 ± 3.8   | 0.970 |      |      |      |
| Hb            | 109.9 ± 18.5 | 114.2 ± 16.9 | 116.7 ± 21.4 | 0.259 |      |      |      |

BMI: body mass index, TBil: total bilirubin, ALB: albumin, Hb: hemoglobin

Table 2 Perioperative outcomes

|                      | OPD (n = 86) | LPD (n = 21) | RPD (n = 32) | P     | p1   | p2   | p3   |
|----------------------|--------------|--------------|--------------|-------|------|------|------|
| Operation time       | 441.5 ± 119.8| 592.9 ± 204.7| 537.2 ± 26.7 | 0.000 | 0.001| 0.000| 1.000|
| Blood loss           | 531.7 ± 555.1| 559.5 ± 427.1| 482.8 ± 663.4| 0.053 |      |      |      |
| Blood transfusion    | 640.4 ± 794.3| 401.4 ± 198.7| 400.9 ± 852.1| 0.343 |      |      |      |
| Conversion to open   | NA           | 8 (38.1)     | 2 (6.5)      | 0.111 |      |      |      |
| Lymph node yield     | 9.0 ± 8.5    | 9.0 ± 9.4    | 6.5 ± 10.7   | 0.913 |      |      |      |
| Abdominal drainage tube removal | 17.3 ± 8.9 | 18.9 ± 13.9 | 12.5 ± 6.3 | 0.002 | 1.000 | 0.001 | 0.177 |
| Catheter removal     | 3.1 ± 1.7    | 2.3 ± 1.4    | 2.7 ± 1.8    | 0.047 | 0.031 | 0.096 | 0.518 |
| ADL on postoperative day 3 | 28.9 ± 12.0 | 25.7 ± 7.1  | 34.8 ± 16.3 | 0.046 | 0.236 | 0.064 | 0.017 |
| Pain Score on postoperative day 3 | 1.4 ± 0.9 | 1.5 ± 0.6 | 1.1 ± 0.8 | 0.158 | | | |
| Length of stay       | 31.2 ± 12.2  | 300 ± 13.7   | 28.8 ± 10.1  | 0.502 |      |      |      |

ADL: activity of daily living, Scale, p1 p value for OPD compared to LPD, p2 p value for OPD compared to RPD, p3 p value for LPD compared to RPD

Table 3 Postoperative complications

|                      | OPD (n = 86) | LPD (n = 21) | p1    | RPD (n = 32) | p2    | p3    |
|----------------------|--------------|--------------|-------|--------------|-------|-------|
| POPF (B/C)           |              |              |       |              |       |       |
| B                    | 17 (19.8%)   | 2 (9.5%)     | 0.434 | 3 (9.4%)     | 0.181 | 1.000 |
| C                    | 2 (2.3%)     | 1 (4.8%)     | 0.484 | 3 (9.4%)     | 0.240 | 0.928 |
| PPH                  | 6 (7.0%)     | 1 (4.8%)     | 1.000 | 3 (9.4%)     | 0.963 | 0.928 |
| Bile leakage         | 17 (19.8%)   | 3 (14.3%)    | 0.791 | 4 (12.5%)    | 0.359 | 1.000 |
| IAI                  | 17 (19.8%)   | 4 (19.0%)    | 1.000 | 6 (18.8%)    | 0.901 | 1.000 |
| Reoperation          | 5 (5.8%)     | 2 (9.5%)     | 0.901 | 2 (6.2%)     | 1.000 | 1.000 |
| Perioperative mortality | 2 (2.3%)   | 0 (0)        | 1.000 | 3 (3.1%)     | 1.000 | 1.000 |

POPF: postoperative pancreatic fistula, PPH: post-pancreatectomy hemorrhage, IAI: intra-abdominal infection, p1 p value for OPD compared to LPD, p2 p value for OPD compared to RPD, p3 p value for LPD compared to RPD
on postoperative day 3 was likely influenced by the lower conversion rate to OPD, but in the subgroups of LPD and RPD cases not converted to OPD, the RPD subgroup still had higher ADL on postoperative day 3 (32.5 vs. 23.0, p = 0.013).

Discussion

RPD has been used in removing various benign and malignant tumors from the head of the pancreas and the periampullary region in recent years, but its adoption remains limited to a few large academic centers, so the availability of associated data is extremely poor. There is no general consensus on the feasibility and safety of RPD and whether it increases surgical risks.

In this study, the RPD, LPD, and OPD groups were fairly similar with regard to most baseline information, such as age, sex, BMI, and tumor size. Accordingly, we believe that the comparison of outcomes among the groups is reliable. Of note, no statistically significant difference in operative time was observed between RPD and LPD, which agrees with the result reported by Zimmerman et al. [22]. Moreover, we noticed that OPD required the least operative time and RPD required the most operative time. The high operative time of RPD was caused by technical difficulties such as the installation and adjustment of robotic arms, especially when the assistants and/or scrub nurses were not well trained or unacquainted with the setup. As robotic technology is developed, the operating time of RPD should be remarkably reduced in the future. We found that blood loss was lower in the RPD group than the OPD and LPD groups, but the difference was not statistically significant. This was similar to the results of Shi et al., who demonstrated that RPD was superior to OPD in estimated blood loss (mean: 297.3 ml vs. 415.2 ml), with a statistically significant difference (p = 0.002) [23]. Furthermore, in an American multi-center study, scientists discovered that RPD offered a mean reduction in blood loss of 181 ml compared to OPD [24]. Interestingly, when Orti-Rodriguez et al. compared an LPD group of 147 patients and an RPD group of 284 patients, the estimated blood loss was significantly higher in the RPD group than in the LPD group (median: 346.44 ml vs. 172.93 ml, p < 0.05) [25]. This discrepancy from our results might stem from patient selection bias and a learning curve.

Additionally, a lower incidence of conversion to OPD was found in the RPD group compared with the LPD group (6.5% vs. 38.1%). This has been corroborated by other published series comparing robotic and laparoscopic approaches [26–28]. More specifically, advantages offered by the robotic approach, including 3D visualization and increased flexibility of the instrument, facilitate the completion of complex resection and digestive tract reconstruction when compared with the laparoscopic approach.

A comparative study between an RPD group with 304 cases and an OPD group with 172 cases by Shyr et al. illustrated that 4.8% of all RPD cases were converted OPD. Remarkably, in the first 100 RPD cases, the conversion rate was roughly 10%, but this figure declined to 7% after 200 cases, and 2.9% after 300 cases, which indicated that the accumulation of experience in surgery could be a dependable predictor of conversion rate [29, 30]. It is widely believed that one of the advantages of robotic and laparoscopic approaches is the reduction of inpatient time [31]. In fact, in a trial by Adam et al., no difference was discovered in hospital stay among 7061 RPD, LPD and OPD patients, including 6078 OPD patients, from the National Cancer Database, which is consistent with our results [32]. The probable reason for this finding in our study is that only a small proportion of the hospital stay is paid for by patients, as most of the stay is covered by medical insurance; hence, patients prefer to remain in the hospital until there is no need to worry about their health issues. We think this could be one of the reasons why the length of hospital stay was higher in our center as compared with most centers in other countries. Additionally, in a recent meta-analysis, Doula et al. [33] reported their findings to be inconclusive as to whether LPD or RPD decreased hospitalization stay. Furthermore, in our study, RPD required less time to remove the abdominal drainage tube than the OPD group (12.5 d vs. 17.3 d, p = 0.001), which may be due to the fact that Da Vinci robotic surgery could decrease inflammatory stress response and peritoneal exudate caused by surgical trauma, as reported by Shibata and his co-workers in 2015 [34]. We also found that there was higher ADL on postoperative day 3 in the RPD group than the LPD group (35.8 vs. 25.7, p = 0.0017). The low conversion rate from RPD to OPD may lead to quicker recovery [35], which could be one of the reasons for this result. In our center, the indications for abdominal drain removal are related to the characteristics and volume of drainage fluid, biochemical examination results (amylase, bilirubin), and bacterial culture results, but we need to be cautious about the removal of the abdominal drainage to prevent the catastrophic consequences of delayed biliary or pancreatic leakage, so the time of the abdominal drainage removal should be decided according to the actual situation.

No significant differences were found in the postoperative complications, such as POPF, PPH, bile leakage, reoperation, and perioperative mortality, among OPD, LPD and RPD. Therefore, RPD appeared not to compromise surgical outcomes, although this retrospective study has limitations due to unavoidable selection bias.
Of note, there are some undeniable limitations in this study. This was a single-center retrospective study with a small sample size, and it lacked randomized controlled trials (RCTs). Additionally, the surgeons in this study were likely still in the early phase of the learning curve of RPD. Further high-quality validation studies are urgently needed.

Conclusions
This study demonstrates that not only is RPD feasible and reliable for the removal of benign and malignant tumors, but it also offers additional benefits in short-term operative outcomes without increasing the surgical risks. In the future, studies involving numerous subjects and large-scale RCTs are required to establish solid conclusions.

Abbreviations
PD: Pancreatoduodenectomy; OPD: Open pancreatoduodenectomy; LDP: Laparoscopic pancreatoduodenectomy; RPD: Robotic pancreatoduodenectomy; ADL: Activity of Daily Living Scale; BMI: Body mass index; POPF: Postoperative pancreatic fistula; ISGPF: International Study Group for Pancreatic Fistula; PPH: Post-pancreatectomy hemorrhage; ISGPS: International Study Group of Pancreatic Surgery; ISLGS: International Study Group of Liver Surgery; IAI: Intra-abdominal infection; SIS: Surgical Infection Society; TBil: Total bilirubin; ALB: Albumin; Hb: Hemoglobin; RCTs: Randomized controlled trials.

Acknowledgements
We gratefully acknowledge the contribution of the participating doctors: Guozhen Huang, Jie Wei, Yong Wang, and Jiaping Liu.

Author contributions
SY, GY and SH conceptualized and designed the study, and they also assisted with drafting or revision of the paper. WG and XY wrote the manuscript and collected the data. JL and SL performed data analysis and assisted with proof-reading. MW, ZW and JY assisted with collecting the data and revision of the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by National Natural Science Foundation of China (91949122), Guangxi Key Research and Development Plan (2018AD03001), The 111 Project (D17011), Key Laboratory Base of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning 530021, Guangxi, China. The datasets of the current study are available from the corresponding author of our first 59 cases of robotic pancreaticoduodenectomy. J Visc Surg. 2019;156(3):185–90.

Available data and materials
The datasets of the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by institutional review board of the First Affiliated Hospital of Guangxi Medical University (approval number:2022KY-E-034), and all methods were carried out in accordance with Declaration of Helsinki. All patients or their authorizers gave written informed consent before the operation.

Consent for publication
Written informed consent was obtained from the patients and/or their legal guardians for publication.

Competing interests
There are no competing financial interests.

Author details
1 Division of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China. 2 Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning 530021, Guangxi, China. 3 Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Nanning 530021, Guangxi, China.

Received: 21 July 2022 Accepted: 13 September 2022
Published online: 22 September 2022

References
1. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. Ann Surg. 1935;102(4):763–79.
2. Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc. 1994;8(5):408–10.
3. Zenoni SA, Arnoletti JP, de la Fuente SG. Recent developments in surgery: minimally invasive approaches for patients requiring pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):115–47.
4. de Rooij TJ, Mekhri-Ben M, et al. Minimally invasive versus open pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and registry studies. Ann Surg. 2016;264(2):257–67.
5. Nasseur I, Wang SC, Christie A, et al. Minimally invasive versus open pancreatoduodenectomy: a propensity-matched study from a national cohort of patients. Ann Surg. 2018;268(1):151–7.
6. Chopnet S, Fuku D, Rinaudo M, et al. Postoperative bleeding after laparoscopic pancreatoduodenectomy: the Achilles’ Heel? World J Surg. 2018;42(4):1138–46.
7. Kutlu OC, Lee JE, Katz MH, et al. Open pancreatoduodenectomy case volume predicts outcome of laparoscopic approach: a population-based analysis. Ann Surg. 2018;267(3):552–60.
8. Giulianiotti PC, Coratti A, Anglèl M, et al.Robotics in general surgery: personal experience in a large community hospital. Arch Surg. 2003;138(7):777–84.
9. Wang SE, Shyr BU, Chen SC, et al. Comparison between robotic and open pancreatoduodenectomy with modified Blumgart pancreaticojejunoscopy: a propensity score-matched study. Surgery. 2018;164(6):1162–7.
10. Guerra F, Checchi P, Vegni A, et al. Surgical and oncological outcomes of our first 59 cases of robotic pancreatoduodenectomy. J Visc Surg. 2019;156(3):185–90.
11. Del Chiario M, Sengersvård R. The state of the art of robotic pancreatectomy. Biomed Res Int. 2014;2014:1–5.
12. Girgis MD, Zenati MS, Steve J, et al. Robotic approach mitigates perioperative morbidity in obese patients following pancreatoduodenectomy. HPB (Oxford). 2017;19(2):93–8.
13. Sommerville CA, Limongelli P, Pai M, et al. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. J Surg Oncol. 2009;100(8):651–6.
14. de Rooij TJ, van Hilist J, Topal B, et al. Outcomes of a multicenter training program in laparoscopic pancreatoduodenectomy (LAELAPS-2). Ann Surg. 2019;269(2):344–50.
15. de Rooij TJ, van Hilist J, Bosscha K, et al. Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. Trials. 2018;19(1):1.
16. Giulianiotti PC, Mangano A, Bustos RE, et al. Operative technique in robotic pancreatoduodenectomy (RPD) at University of Illinois at Chicago (UIC): 17 steps standardized technique: lessons learned since the first worldwide RPD performed in the year 2001. Surg Endosc. 2018;32(10):4329–36.
17. Bassi C, Marchegiani G, Dervens C, et al. The 2016 update of the International Study Group on Pancreatic Surgery (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.
18. Wente MN, Veit JA, Bassi C, et al. Postpancreactectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1):20–5.
19. Koch M, Garden OJ, Padbury R, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011;149(5):680–8.
20. Soltomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–64.
21. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
22. Zimmerman AM, Royle DG, Charpentier KP. A comparison of outcomes between open, laparoscopic and robotic pancreaticoduodenectomy. HPB (Oxford). 2018;20(4):364–9.
23. Shi Y, Jin J, Qiu W, et al. Short-term outcomes after robot-assisted vs open pancreaticoduodenectomy after the learning curve. JAMA Surg. 2020;155(3):389–94.
24. Zureikat AH, Postlewait LM, Liu Y, et al. A multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. Ann Surg. 2016;264(4):640–9.
25. Ortiz-Rodríguez RJ, Rahman SH. A comparative review between laparoscopic and robotic pancreaticoduodenectomies. Surg Laparosc Endosc Percutan Tech. 2014;24(2):103–8.
26. Nassour I, Wang SC, Porembka MR, et al. Robotic versus laparoscopic pancreaticoduodenectomy: a NSQIP analysis. J Gastrointest Surg. 2017;21(11):1784–92.
27. Zhou NX, Chen JZ, Liu Q, et al. Outcomes of pancreaticoduodenectomy with robotic surgery versus open surgery. Int J Med Robot. 2011;7(2):131–7.
28. Tsung A, Geller DA, Sukato DC, et al. Robotic versus laparoscopic hepatectomy: a matched comparison. Ann Surg. 2014;259(5):549–55.
29. Shyr BU, Shyr BS, Chen SC, et al. Robotic and open pancreaticoduodenectomy: results from Taipei Veterans General Hospital in Taiwan. Updates Surg. 2021;73(3):939–46.
30. de Rooij T, van Hilst J, Boerma D, et al. Impact of a nationwide training program in minimally invasive distal pancreatectomy (LAELAPS). Ann Surg. 2016;264(5):754–62.
31. Tran TB, Dua MM, Worhunsky DJ, et al. The first decade of laparoscopic pancreaticoduodenectomy in the United States: costs and outcomes using the nationwide inpatient sample. Surg Endosc. 2016;30(5):1778–83.
32. Adam MA, Choudhury K, Dinan MA, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg. 2015;262(2):372–7.
33. Doula C, Kostakis ID, Damaskos C, et al. Comparison between minimally invasive and open pancreaticoduodenectomy: a systematic review. Surg Laparosc Endosc Percutan Tech. 2016;26(1):6–16.
34. Shibata J, Ishihara S, Tada N, et al. Surgical stress response after colorectal resection: a comparison of robotic, laparoscopic, and open surgery. Tech Coloproctol. 2015;19(5):275–80.
35. Kamarajah SK, Bunded J, Marc OS, et al. Robotic versus conventional laparoscopic pancreaticoduodenectomy: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(1):6–14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions